Scholarlink

<p>Invasive fungal disease (IFD) remains a challenging complication and a leading cause of death in the treatment of childhood acute leukemia (AL). Blinatumomab is a novel bispecific antibody targeting CD19, with excellent anti-tumor effects against B cell malignancies, including B cell acute lymphoblastic leukemia (B-ALL). Compared with standard chemotherapy, blinatumomab causes less immunosuppression. This report describes two children with B-ALL who experienced recurrent high fever during induction chemotherapy. Next-generation sequencing (NGS) detected Aspergillus in bronchoalveolar lavage fluid, skin tissue, blood, and cerebrospinal fluid. After antifungal therapy, the patients received 9 courses of blinatumomab combined with reduced-dose chemotherapy. Symptoms, signs, and imaging findings improved significantly, B-ALL remained in continuous remission in both patients, and no cytokine release syndrome, neurotoxicity, or fungal infection recurrence occurred. These cases suggest that alternating blinatumomab with reduced-dose chemotherapy is both effective and safe for patients with B-ALL suffering life-threatening infections in the setting of ALL therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月30日

查看全文
  • En-Min Zhou,
  • Yongmin Tang,
  • Chan Liao,
  • Shupeng Lin,
  • Heping Shen,
  • Di Wang,
  • Liyao Xu,
  • Ping Zhang,
  • Hua Song,
  • Xiaojun Xu,
  • Jingying Zhang,
  • Juan Liang,
  • Diying Shen,
  • Fenying Zhao,
  • Weiqun Xu

摘要

Invasive fungal disease (IFD) remains a challenging complication and a leading cause of death in the treatment of childhood acute leukemia (AL). Blinatumomab is a novel bispecific antibody targeting CD19, with excellent anti-tumor effects against B cell malignancies, including B cell acute lymphoblastic leukemia (B-ALL). Compared with standard chemotherapy, blinatumomab causes less immunosuppression. This report describes two children with B-ALL who experienced recurrent high fever during induction chemotherapy. Next-generation sequencing (NGS) detected Aspergillus in bronchoalveolar lavage fluid, skin tissue, blood, and cerebrospinal fluid. After antifungal therapy, the patients received 9 courses of blinatumomab combined with reduced-dose chemotherapy. Symptoms, signs, and imaging findings improved significantly, B-ALL remained in continuous remission in both patients, and no cytokine release syndrome, neurotoxicity, or fungal infection recurrence occurred. These cases suggest that alternating blinatumomab with reduced-dose chemotherapy is both effective and safe for patients with B-ALL suffering life-threatening infections in the setting of ALL therapy.